Eisai (ESALY) Rating Increased to Hold at Zacks Investment Research

Share on StockTwits

Eisai (OTCMKTS:ESALY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “

ESALY traded down $0.36 during trading on Wednesday, reaching $88.30. 2,482 shares of the stock traded hands, compared to its average volume of 4,804. The stock has a market cap of $24.94 billion, a price-to-earnings ratio of 54.17 and a beta of 0.17. Eisai has a fifty-two week low of $49.86 and a fifty-two week high of $101.80. The company has a current ratio of 2.20, a quick ratio of 1.92 and a debt-to-equity ratio of 0.26.

Eisai Company Profile

Eisai Co, Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals worldwide. It offers Halaven and Lenvima, an anticancer agent; Aloxi, an antiemetic agent; Aricept, a treatment for Alzheimer's disease; Fycompa, an antiepileptic agent; Methycobal for peripheral neuropathy treatment; BELVIQ for anti-obesity treatment; and LYRICA for neuropathic pain treatment.

Read More: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on Eisai (ESALY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply